Patents Assigned to Medizinische Universitat Innsbruck
-
Patent number: 11839394Abstract: The present invention relates to a reflector for an acoustic shock or pressure wave head, wherein the reflector comprises an acoustically reflective surface formed by a body of rotation, said body of rotation being formed by rotation of an elliptical segment about a rotation axis which extends through a focal point of the ellipse and encloses an angle ? between 0.1° and 30° with the main axis of the ellipse.Type: GrantFiled: June 25, 2021Date of Patent: December 12, 2023Assignees: Medizinische Universität Innsbruck, Heart Regeneration Technologies GMBHInventors: Christian Dorfmüller, Johannes Holfeld, Michael Grimm
-
Patent number: 11674923Abstract: The present invention relates to a single-use test-strip for the quantitative determination of sodium concentration and creatinine concentration and for the subsequent determination of their ratio, and to a non-invasive point-of-care (POC) device for detecting sodium depletion and/or sodium overload in a patient's body. Furthermore, the present invention relates to a method for simultaneously and quantitatively determining sodium concentration and creatinine concentration in a patient's urine sample and to a method of detecting sodium depletion and/or sodium overload in a patient's body.Type: GrantFiled: March 20, 2018Date of Patent: June 13, 2023Assignees: UNIVERSITÄT INNSBRUCK, MEDIZINISCHE UNIVERSITÄT INNSBRUCKInventors: Peter Heinz-Erian, Gerda Laura Fuhrmann
-
Publication number: 20210363545Abstract: The present invention relates to a method of site-directed integration into a genetic locus encoding at least one activity of the pyrimidine salvage pathway in a host cell, wherein said activity of the pyrimidine salvage pathway is purine/cytosine permease (FcyB), cytosine deaminase (FcyA), uracil-phosphoribosyl-transferase (Uprt), concentrative nucleoside transporter (CntA) or uridine kinase (UK), comprising: a) providing a host cell comprising a functional copy of the genetic locus encoding at least one activity of the pyrimidine salvage pathway; (b) introducing a gene or sequence of interest into said host cell via transformation of an integrative nucleic acid construct which comprises 3? and/or 5? of the gene or sequence of interest flanks being homologous to said genetic locus or which carries a sequence being homologous to said genetic locus of the pyrimidine salvage pathway and thus allowing for a homologous recombination at said genetic locus, wherein said homologous recombination is capable of causinType: ApplicationFiled: June 7, 2019Publication date: November 25, 2021Applicant: Medizinische Universität InnsbruckInventors: Fabio GSALLER, Hubertus HAAS
-
Patent number: 11096706Abstract: The present invention relates to a reflector for an acoustic shock or pressure wave head, wherein the reflector comprises an acoustically reflective surface formed by a body of rotation, said body of rotation being formed by rotation of an elliptical segment about a rotation axis which extends through a focal point of the ellipse and encloses an angle ? between 0.1° and 30° with the main axis of the ellipse.Type: GrantFiled: October 21, 2015Date of Patent: August 24, 2021Assignees: Medizinische Universität Innsbruck, Heart Regeneration Technologies GMBHInventors: Christian Dorfmüller, Johannes Holfeld, Michael Grimm
-
Patent number: 11091490Abstract: The present invention relates to 3-amino-pyrazolo[3,4-d]pyrimidin-4-ones, such as for example, N-{4-[1-(2,6-dichloro-4-sulfamoyl-phenyl)-3-dimethylamino-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-ylmethyl]-phenyl}-2-diethylamino-acetamide, particularly useful as cyclin dependent kinase (CDK) inhibitors, pharmaceutical compositions comprising the same and the use thereof in particular in the prophylaxis and/or treatment of cancer and other proliferative diseases. Furthermore, the present invention relates to processes for the synthesis of said 3-aminopyrazolo[3,4d]pyrimidin-4-ones and intermediates to be used in the processes of the present invention.Type: GrantFiled: November 29, 2017Date of Patent: August 17, 2021Assignees: MEDIZINISCHE UNIVERSITÄT INNSBRUCK, Vichem Chemie Kutató Korlátolt Felelösségü TársaságInventors: Winfried Wunderlech, Lukas A. Huber, Johann Jakob Leban, János Pató, László Örfi, Wáczek Frigyes, Péter Bánhegyi, Anna Sípos, Csaba Szántai-kis
-
Patent number: 11033373Abstract: The present disclosure relates to an intraoral suctioning device for intraoral negative pressure wound treatment and a method for manufacturing the same. In order to permanently maintain the negative pressure in a wound with a view to an improved wound treatment and regeneration process, the intraoral suctioning device for the intraoral negative pressure wound treatment as disclosed can include a dental splint, an elastic membrane sealing an aperture formed in the dental splint so as to define a sealed wound treatment area on the inside of the dental splint, and a suctioning channel system for evacuating the wound treatment area.Type: GrantFiled: November 21, 2017Date of Patent: June 15, 2021Assignee: MEDIZINISCHE UNIVERSITÄT INNSBRUCKInventors: Johannes Laimer, Emanuel Bruckmoser
-
Publication number: 20190374322Abstract: The present disclosure relates to an intraoral suctioning device for intraoral negative pressure wound treatment and a method for manufacturing the same. In order to permanently maintain the negative pressure in a wound with a view to an improved wound treatment and regeneration process, the intraoral suctioning device for the intraoral negative pressure wound treatment as disclosed can include a dental splint, an elastic membrane sealing an aperture formed in the dental splint so as to define a sealed wound treatment area on the inside of the dental splint, and a suctioning channel system for evacuating the wound treatment area.Type: ApplicationFiled: November 21, 2017Publication date: December 12, 2019Applicant: Medizinische Universität InnsbruckInventors: Johannes LAIMER, Emanuel BRUCKMOSER
-
Patent number: 10369522Abstract: Electrochemical cell array for the treatment of a sample via electro-(end-)osmotic flow, comprising (i) an electrode chamber, comprising a cathodic compartment (CC) and an anodic compartment (AC), (ii) a cathode (C), being arranged in the cathodic compartment (CC), (iii) an anode (A), being arranged in the anodic compartment (AC), (iv) an intermediate cathodic compartment (C1) (v) an intermediate anodic compartment (A1) (iv) a first selective membrane (M1) being arranged between said cathodic compartment (CC) and said first intermediate cathodic compartment (C1) (v) a second selective membrane (M2) being arranged between said anodic compartment (AC) and said first intermediate anodic compartment (A1) (vi) a treatment compartment (T) for the sample being arranged between said intermediate cathodic compartment (C1) and said intermediate anodic compartment (A1), further comprising a first separator membrane (S1) between said treatment compartment (T) and said intermediate cathodic compartment (C1) and a seconType: GrantFiled: December 23, 2014Date of Patent: August 6, 2019Assignees: UNIVERSITAT INNSBRUCK, MEDIZINISCHE UNIVERSITAT INNSBRUCKInventors: Markus Kofler, Julia Dumpfarth, Michael Grimm, Georg Grimm, Gulnara Fauland, Thomas Bechtold
-
Publication number: 20190010547Abstract: The present invention relates to a predictive diagnostic method for identifying whether a patient will develop metabolic syndrome and/or type-2 diabetes in the future. In particular, the invention relates to a method for identifying a subject which has a risk for developing metabolic syndrome and/or type-2 diabetes, wherein the method comprises (a) analyzing (i.e. determining/measuring/quantifying) in a sample obtained from a test subject the amount of miR-122; and (b) identifying (i.e. detecting) a subject, which has a risk for developing metabolic syndrome and/or type-2 diabetes, wherein an increased amount of miR-122 as compared to the amount of miR-122 of a healthy reference population indicates a risk for developing metabolic syndrome and/or type-2 diabetes. Another aspect of the invention relates to a method for monitoring the therapeutic success during the treatment of metabolic syndrome and/or type-2 diabetes, wherein the method comprises (a) analyzing (i.e.Type: ApplicationFiled: November 4, 2016Publication date: January 10, 2019Applicants: Medizinische Universität Innsbruck, King's College LondonInventors: Peter Willeit, Manuel Mayr, Johann Willeit, Stefan Kiechl
-
Publication number: 20160325230Abstract: Electrochemical cell array for the treatment of a sample via electro-(end-)osmotic flow, comprising (i) an electrode chamber, comprising a cathodic compartment (CC) and an anodic compartment (AC), (ii) a cathode (C), being arranged in the cathodic compartment (CC), (iii) an anode (A), being arranged in the anodic compartment (AC), (iv) an intermediate cathodic compartment (C1) (v) an intermediate anodic compartment (A1) (iv) a first selective membrane (M1) being arranged between said cathodic compartment (CC) and said first intermediate cathodic compartment (C1) (v) a second selective membrane (M2) being arranged between said anodic compartment (AC) and said first intermediate anodic compartment (A1) (vi) a treatment compartment (T) for the sample being arranged between said intermediate cathodic compartment (C1) and said intermediate anodic compartment (A1), further comprising a first separator membrane (S1) between said treatment compartment (T) and said intermediate cathodic compartment (C1) and a seconType: ApplicationFiled: December 23, 2014Publication date: November 10, 2016Applicants: UNIVERSITÄT INNSBRUCK, MEDIZINISCHE UNIVERSITÄT INNSBRUCKInventors: Markus Kofler, Julia Dumpfarth, Michael Grimm, Georg Grimm, Gulnara Fauland, Thomas Bechtold
-
Patent number: 8809288Abstract: The invention relates to an in vitro or ex vivo method for increasing the immunoreactivity of cells of the immune system, which were contacted with an antigen, said method comprising the reduction or inhibition of the Cbl-b function of said cells, thereby increasing the immunoreactivity of the cells towards the antigen.Type: GrantFiled: December 10, 2008Date of Patent: August 19, 2014Assignees: Medizinische Universitat Innsbruck, Apeiron Biologics AGInventors: Gottfried Baier, Hans Loibner, Manfred Schuster, Gunther Lametschwandtner, Dominik Wolf
-
Patent number: 8623607Abstract: The present invention relates to a method for determining or predicting the progression of chronic kidney disease in a subject suspected of having chronic kidney disease, comprising determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention.Type: GrantFiled: October 25, 2011Date of Patent: January 7, 2014Assignee: Medizinische Universitat InnsbruckInventors: Florian Kronenberg, Barbara Kollerits, Danilo Fliser
-
Patent number: 8335034Abstract: The present invention provides an optical device comprising a pair of specifically designed plate-like diffractive optical elements successively arranged in parallel to each other. Placing the two diffractive optical elements in succession and in parallel to each other in a certain distance, the combination optically corresponds to a single diffractive optical element, and it can perform similar tasks, acting as a lens, an axicon, a phase shifter, or a spiral phase plate. If one of the diffractive optical elements is rotated with respect to the other around a common central axis, the property of the optical device, like the focal length, the refractive power, helical index, or phase shift changes continuously.Type: GrantFiled: July 20, 2007Date of Patent: December 18, 2012Assignee: Medizinische Universitat InnsbruckInventors: Stefan Bernet, Monika Ritsch-Marte
-
Patent number: 8058015Abstract: The present invention relates to a method for the determination or prediction of the progression of chronic kidney disease in a subject suspected to suffer from chronic kidney disease, said method comprising the step of determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or use of a specific detection molecule for adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention.Type: GrantFiled: January 21, 2008Date of Patent: November 15, 2011Assignee: Medizinische Universität InnsbruckInventors: Florian Kronenberg, Barbara Kollerits, Danilo Fliser
-
Publication number: 20110239311Abstract: The present invention relates to agonists/activators of NR2F6 (nuclear orphan receptor receptor Ear2) for the treatment of a disease related to an augmented immune response. Furthermore, pharmaceutical compositions comprising said agonists/activators of NR2F6 and a pharmaceutical carrier are comprised. In a further aspect, the present invention provides for a method for identifying immunosuppressants comprising contacting a cell, tissue or a non-human animal comprising a reporter construct for NR2F6-activation with a candidate molecule, measuring the reporter signal and selecting a candidate molecule which alters the reporter signal. Furthermore, the present invention relates to non-human transgenic animals or cells or tissue derived therefrom useful in the provided methods for identifying immunosuppressants.Type: ApplicationFiled: January 11, 2011Publication date: September 29, 2011Applicant: Medizinische Universitat InnsbruckInventors: Gottfried Baier, Natascha Hermann-Kleiter
-
Publication number: 20110236427Abstract: The present invention relates to antagonists/inhibitors of NR2F6 (nuclear orphan receptor receptor Ear2) for the treatment of a disease related to an insufficient immune response. Furthermore, pharmaceutical compositions comprising said antagonists/inhibitors of NR2F6 and a pharmaceutical carrier are comprised. In a further aspect, the present invention provides for a method for identifying immunoaugmenting agents comprising contacting a cell, tissue or a non-human animal comprising a reporter construct for NR2F6-inhibition with a candidate molecule, measuring the reporter signal and selecting a candidate molecule which alters the reporter signal. Furthermore, the present invention relates to the non-human transgenic animals or cells or tissue derived therefrom useful in the provided methods for identifying immunoaugmenting agents.Type: ApplicationFiled: January 11, 2011Publication date: September 29, 2011Applicant: Medizinische Universitat InnsbruckInventors: Gottfried Baier, Natascha Hermann-Kleiter
-
Publication number: 20110189252Abstract: The present invention relates to a pharmaceutical composition comprising specific compounds which may be obtained from Leontopodium alpinum Cass. (Edelweiss). A preferred compound is leoligin (=(2S,3R,4R)-4-(3,4-dimethoxybenzyl)-2-(3,4-dimethoxyphenyl)tetrahydrofuran-3-yl]methyl(2Z)-2-methylbut-2-enoat]). Corresponding means and methods in respect of medical uses of the compounds are described. The present invention also provides a medical device comprising, containing or having been contacted with the compound. The compounds provided herein may particularly be used in the treatment of hyperplastic diseases, in particular intimal hyperplasia, e.g. stenosis, restenosis, atherosclerosis and the like. Also envisaged herein is the use of these compounds in the treatment of proliferative diseases, such as leukemia, prostate cancer and lung cancer.Type: ApplicationFiled: July 17, 2009Publication date: August 4, 2011Applicant: MEDIZINISCHE UNIVERSITÄT INNSBRUCKInventors: Hermann Stuppner, Stefan Schwaiger, David Bernhard, Günther Laufer
-
Publication number: 20110159018Abstract: The present invention relates to a complement activating construct comprising a complement factor H-derived short consensus repeat (fH-derived SCR) and a binding molecule which specifically recognizes a pathogen. More specifically, the fH-derived SCR is selected from the group consisting of SCR7, SCR9, SCR13, SCR18-20 and artificial SCR (aSCR). Furthermore, an in vivo method for screening complement-based approaches for the treatment of the prevention, treatment or amelioration of an infection with a pathogen or a pathological condition associated with an infection with a pathogen is described.Type: ApplicationFiled: May 2, 2008Publication date: June 30, 2011Applicant: Medizinische Universitat InnsbruckInventor: Heribert Stoiber
-
Publication number: 20100260808Abstract: The invention relates to an in vitro or ex vivo method for increasing the immunoreactivity of cells of the immune system, which were contacted with an antigen, said method comprising the reduction or inhibition of the Cbl-b function of said cells, thereby increasing the immunoreactivity of the cells towards the antigen.Type: ApplicationFiled: December 10, 2008Publication date: October 14, 2010Applicants: MEDIZINISCHE UNIVERSITAT INNSBRUCK, APEIRON BIOLOGICS AGInventors: Gottfried Baier, Hans Loibner, Manfred Schuster, Gunther Lametschwandtner, Dominik Wolf
-
Publication number: 20100143951Abstract: The present invention relates to a method for the determination or prediction of the progression of chronic kidney disease in a subject suspected to suffer from chronic kidney disease, said method comprising the step of determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or use of a specific detection molecule for adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention.Type: ApplicationFiled: January 21, 2008Publication date: June 10, 2010Applicant: Medizinische Universitat InnsbruckInventors: Florian Kronenberg, Barbara Kollerits, Danilo Fliser